Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

Publisher: La Merie Publishing
Format: PDF
Product Line:
LMP Full Report
Product Code: LMFR0021
Release Date: September of 2016

4,500.00 €
(Discount: 33.33%)
3,000.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Indirect T-cell therapy leverages the capability of tumor-targeted bispecific antibodies to redirect T-cells to the tumor. This report package includes two full reports covering both aspects of T-cell immunotherapy of cancer.

The original reports were published in May and August 2016, respectively:

Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.

 


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top